Welcome To Compact
Therapeutic modalities based on macromolecules of biological origin such as proteins, peptides and oligonucleotides have a huge pharmacological potential due to their highly selective mode of action and their potential activity against targets that are considered ‘non-druggable’ by more traditional small organic molecules.
However, the widespread application of many potential macromolecular therapeutics has been very limited due to pharmacokinetic and drug disposition limitations at both the tissue and cellular level. Therefore, their success in developing future innovative medicines will heavily depend on improvements in both chemistries and delivery technologies that can address these limitations.
Therefore leading European experts from sixteen academic research institutions and SME as well as seven pharmaceutical industry research organizations in the area of delivery and uptake of biological macromolecules officially launched the COMPACT project on November 1st, 2011.
The close cooperation of academic teams, pharmaceutical companies and Small to Medium Enterprises (SMEs) in the COMPACT project will provide a unique platform of expertise of an EU-supported public-private partnership to persistently improve industrial competitiveness and Public Health in Europe.
The COMPACT proposal has been published in the fourth call for proposal of the Innovative Medicines Initiative (IMI), which is part of the EU Seventh Framework programme (FP7).
Collaboration on the Optimization of Macromolecular...
Learn more about IMI
The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership... more >>
Learn more about EFPIA
The European Federation of Pharmaceutical Industries and Associations... more >>
Access to the Compact Member Area